Medindia LOGIN REGISTER
Medindia
Advertisement

PacificGMP Completes GMP Product Fill for Trius Therapeutics

Thursday, May 15, 2008 General News
Advertisement
SAN DIEGO, May 14 PacificGMP, the leader in utilizingsingle-use bioprocessing for development and manufacturing for its clientpartners, announced today that it has completed a product fill under GMP (goodmanufacturing practices) standards for a Trius Therapeutics Phase I clinicaltrial.
Advertisement

"We are pleased to have worked closely with Trius on this GMP fillproject, an effort that we were able to initiate quickly and complete within anarrow deadline," said Leigh N. Pierce, president of PacificGMP. "Although ourclient base consists of mainly biologics drug developers, PacificGMP hascompleted projects for a variety of other customers including small moleculedrug developers like Trius, as well as academic institutions and diagnosticscompanies."
Advertisement

"PacificGMP successfully completed our GMP product fill and I appreciatedtheir flexibility and willingness to work with us to get the job done in atimely and professional manner," said Jeffrey Barker, Director ofPharmaceutical Development for Trius Therapeutics.

About PacificGMP

PacificGMP is a contract manufacturing organization (CMO) and industryleader in utilizing single-use bioprocessing for development and manufacturingof biologics. Single-use technology eliminates the risk ofcross-contamination, has fewer system requirements and significantly reducesthe time required to initiate production. Benefits to clients include rapidproject turnaround and the most cost effective solution in the industry.PacificGMP provides cGMP and non-GMP services ranging from cell lineoptimization, early process design, development and scale-up, to preclinicaland clinical biologics manufacturing, purification and fill/finish. Moreinformation can be found by visiting the Company's web site athttp://www.pacificGMP.com.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterialdrugs for the treatment of infections caused by resistant pathogens. Thecompany's lead drug candidate, TR-701 is a novel, oral and IV, oxazolidinoneantibiotic with potent activity against drug-resistant Gram-positive bacterialpathogens including those resistant to Zyvox(R). Trius has licensed worldwiderights outside of Korea to TR-701 from Dong-A Pharmaceuticals. Trius' pipelineincludes two additional structure-based drug design programs directed againstnovel antibacterial targets. For more information, visithttp://www.triusrx.com.Available Topic Expert(s): For information on the listed expert(s), clickappropriate link.Leigh Piercehttp://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=67271 Contact: PacificGMP Gary Pierce Chief Business Officer 858-550-4094

SOURCE PacificGMP
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close